Impact of chronic intranasal oxytocin administration on face expression processing in autistic children: a randomized controlled trial using fMRI

Table 3 Oxytocin versus placebo treatment effect on the change-from-baseline (CFB) activity per ROI during face processing

ROI activity FACES vs. FIX contrast	Oxytocin CFB-value	Placebo CFB-value	Group comparison
ROI activity FACES vs. FIX contrast	Oxytocin CFB-value	Placebo CFB-value	t value	P_unc	P_FDR
V1	0.06	0.13	− 0.51	0.61	0.82
Left inferior occipital	− 0.17*	− 0.02	− 1.65	0.11	0.32
Right inferior occipital	− 0.07	0.01	− 0.87	0.39	0.58
Left posterior fusiform	− 0.16°	0.00	− 1.47	0.15	0.32
Right posterior fusiform	0.03	0.01	0.18	0.86	0.96
Left STS	− 0.18*	0.03	− 2.49	0.02	0.25
Right STS	− 0.03	0.12	− 1.52	0.14	0.32
Left amygdala	− 0.04	− 0.03	− 0.08	0.94	0.96
Right amygdala	− 0.13°	0.03	− 1.57	0.13	0.32
Left anterior temporal	− 0.07	− 0.07	0.05	0.96	0.96
Right anterior temporal	− 0.03	− 0.09	0.99	0.33	0.58
Left inferior frontal	− 0.12°	0.02	− 2.21	0.03	0.25
Right inferior frontal	− 0.16	− 0.06	− 0.93	0.36	0.58

CFB-values with an asterisks (° p < 0.05 uncorrected. * q < 0.05 FDR corrected) indicate whether the T1 versus T0 change-from-baseline contrasts yield significant brain activity within a particular ROI within a particular treatment group based on a one-sample t-test with H₀: Mean X = 0. P-values in bold (p < 0.05) indicate whether the FACESvsFIX contrast yields significant brain activity within a particular ROI between both treatment-groups, based on a two-sample t-test

ISSN: 2040-2392